<DOC>
	<DOCNO>NCT02952248</DOCNO>
	<brief_summary>The main objective dose-escalation part trial determine safety tolerability , Pharmacokinetic ( PK ) , biomarkers , efficacy , determine Maximum Tolerated Dose and/or Recommended Phase 2 Dose ( RP2D ) BI 754091 basis patient dose-limiting toxicity ( DLTs ) patient select advanced solid malignancy . Safety tolerability evaluate monitoring occurrence adverse event ( AEs ) , serious AEs ( SAE ) , laboratory parameter abnormality , well change vital sign . Secondary objective determination PK profile BI 754091 single multiple dos BI 754091 , preliminary assessment antitumour activity . In dose-expansion part trial , main objective assess safety , efficacy , PK profile , biomarkers BI 754091 RP2D .</brief_summary>
	<brief_title>A Trial Find Investigate Safe Dose New Substance ( BI 754091 ) Patients With Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Provision sign date , write Informed Consent Form ( ICF ) prior trialspecific procedure , sample , analysis . If patient decline participate voluntary pharmacogenetics component trial , he/she exclude aspect trial . Patients ≥18 year age time signature ICF Phase Ia ( doseescalation ) patient histologically confirm diagnosis advance , unresectable , and/or metastatic solid tumour ( type ) . Phase Ib ( dose expansion patient confirm diagnosis select advance , unresectable , and/or metastatic solid tumour ( Non Small Cell Lung Cancer , bladder cancer , melanoma , gastric cancer , ovarian cancer , Triple Negative Breast Cancer , Renal Cell Carcinoma ) . All patient must measurable lesion accord Response Evaluation Criteria Solid Tumours ( RECIST ) v1.1 ImmuneRelated Related Response Evaluation Criteria Solid Tumours ( irRECIST ) . Patients antiPD1 naïve fail conventional treatment ( exclude antiPD1 treatment ) , therapy proven efficacy exists , amenable standard therapy . Eastern Cooperative Oncology Group ( ECOG ) score : 0 1 For Phase Ib doseexpansion portion : patient must measurable disease per RECIST v1.1 irRECIST criterion , must least 1 tumour lesion amenable biopsy , must medically fit willing undergo biopsy first treatment , unless clinically contraindicate , 6 week therapy . Patients Phase Ia portion may agree optional paired biopsy . Life expectancy least 12 week start treatment accord Investigator 's judgement Females childbearing potential willing use adequate contraceptive measure time screen 6 month trial discontinuation , breast feeding , agree pregnancy test prior start dose regular visit trial . Females childbearing potential must evidence fulfil one follow criterion screen : Postmenopausal : define 50 yearsofage amenorrhoeic least 12 month follow cessation exogenous hormonal treatment Documentation irreversible surgical sterilization hysterectomy , bilateral oophorectomy , bilateral salpingectomy , tubal ligation . Women 50 yearsofage would consider postmenopausal amenorrhoeic least 12 month follow cessation exogenous hormonal treatment , serum folliclestimulating hormone luteinizing hormone level postmenopausal range institution . For woman childbearing potential use contraceptive pill , additional barrier method necessary . A list adequate contraception method provide patient information . Male patient must willing use barrier contraception ( i.e. , condom ) duration trial 6 month trial treatment discontinuation . Exclusion criterion : Major surgery ( major accord Investigator 's assessment ) perform within 12 week prior first trial treatment plan within 12 month screen , e.g. , hip replacement Patients must wish continue intake restricted medication drug consider likely interfere safe conduct trial Previous enrolment trial Any investigational antitumour treatment within 30 day prior initial administration BI 754091 . History within last 5 year invasive malignancy one treat trial , exception resected/ablated basal squamouscell carcinoma skin carcinoma situ cervix , local tumour consider cured local treatment . Untreated brain metastasis ( es ) may consider active . Patients previously treat brain metastasis may participate provide stable ( i.e. , without evidence Progression Disease image least 4 week prior first dose trial treatment , neurologic symptom return baseline ) , evidence new enlarge brain metastasis Inadequate organ function bone marrow reserve demonstrate follow laboratory value : Absolute neutrophil count &lt; 1.5 x 10^9/L ( &lt; 1500/mm3 ) Platelet count &lt; 100 x 10^9/L Haemoglobin &lt; 90 g/L ( &lt; 9 g/dL ) Alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal ( ULN ) demonstrable liver metastasis &gt; 5 time ULN presence liver metastases Aspartate aminotransferase ( AST ) &gt; 2.5 time ULN demonstrable liver metastasis &gt; 5 time ULN presence liver metastases Total bilirubin &gt; 1.5 time ULN , except patient Gilbert 's syndrome exclude total bilirubin &gt; 3.0 x ULN direct bilirubin &gt; 1.5 x ULN Creatinine &gt; 1.5 time ULN creatinine clearance &lt; 50 mL/min ( measure calculate Cockcroft Gault equation ) ; confirmation creatinine clearance require creatinine &gt; 1.5 time ULN . Any follow cardiac criterion : Mean rest correct QT interval ( QTc ) &gt; 470 msec Any clinically important abnormality rhythm , conduction , morphology rest Electrocardiograms , e.g. , complete leave bundle branch block , third degree heart block Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 yearsofage , concomitant medication know prolong QT interval Ejection fraction &lt; 55 % low limit normal institutional standard . History pneumonitis within last 5 year History severe hypersensitivity reaction monoclonal Antibodies Immunosuppressive corticosteroid dos ( &gt; 10 mg prednisone daily equivalent ) within 4 week prior first dose BI 754091 Active autoimmune disease document history autoimmune disease , except vitiligo resolve childhood asthma/atopy Known history human immunodeficiency virus infection active hepatitis B C virus infection Interstitial lung disease Chronic alcohol drug abuse condition , Investigator 's opinion , make him/her unreliable trial subject , unlikely complete trial , unable comply protocol procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>